cell and gene therapies

News

FDA blocks trials that send US cells to 'hostile' countries

The FDA says it will review clinical trials that send US citizens' cells to 'hostile countries' as the agency's leadership in this area is sidelined.

R&D

Woman, microscope and scientist in research

Advances in manufacturing in vivo lentiviral vectors: Challe...

Lentiviral vectors (LVVs) have proven to be extremely versatile genetic delivery vehicles, gaining space as a gene transfer technology tool used both for cell and gene therapies.

/themes/custom/pharmaphorum_theme/library/img/article-label-image/ondemand.png

R&D

Exploring the future: Opportunities and challenges in cell a...

Rare disease treatment poses distinct challenges for physicians, patients, caregivers, and pharma companies.

News

Bayer gains ground in two-fronted Parkinson's offensive

Bayer's cell therapy for Parkinson's disease is on the brink of a phase 3 trial, while its gene therapy has started phase 2 testing.

News

Amid BIOSECURE Act speculation, WuXi AppTec sells unit

WuXi AppTec has agreed to sell a business unit serving the cell and gene therapy (CGT) sector to private equity firm Altaris for an undisclosed sum

News

Mesoblast finally pushes GvHD cell therapy over finish line

At its third attempt, Mesoblast has secured FDA approval for the first-ever mesenchymal stem cell (MSC) therapy, Ryoncil for acute GvHD in children.

FDA blocks trials that send US cells to 'hostile' countries

Advances in manufacturing in vivo lentiviral vectors: Challe...

Exploring the future: Opportunities and challenges in cell a...

Bayer gains ground in two-fronted Parkinson's offensive

Amid BIOSECURE Act speculation, WuXi AppTec sells unit

Mesoblast finally pushes GvHD cell therapy over finish line

ASCO 2026: Chinese firms take a front seat in oncology, with...

Discover a new era of healthcare panel engagement: Grounded ...

cell and gene therapies

Editor's Picks